Want to see PXMD full AI Analyst Report?
PXMD Stock Chart & Stats
$0.03
<$0.01(13.42%)
At close: 4:00 PM EST
$0.03
<$0.01(13.42%)
Day’s Range― - ―
52-Week Range$0.03 - $1.19
Previous CloseN/A
Volume26.44K
Average Volume (3M)37.62K
Market Cap
$88.39K
Enterprise Value-$4.62M
Total Cash (Recent Filing)$324.49K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta56.60
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding126,264,370
10 Day Avg. Volume1,549
30 Day Avg. Volume37,622
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.12
Enterprise Value/Market Cap-52.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.26
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetHaving no debt enhances financial flexibility and reduces risk, allowing PaxMedica to focus resources on R&D and strategic growth initiatives.
Improved Equity PositionA positive equity position strengthens the balance sheet, providing a buffer against financial instability and supporting future investment opportunities.
Focus On Unmet NeedsTargeting unmet medical needs in neurodevelopmental disorders positions PaxMedica to capture niche markets and potentially secure competitive advantages.
Bears Say
No Revenue GenerationLack of revenue generation raises concerns about the company's ability to sustain operations and achieve profitability, necessitating strategic changes.
Consistent Net LossesOngoing net losses indicate operational inefficiencies and highlight the need for effective cost management and revenue-generating strategies.
Negative Cash FlowsNegative cash flows from operations suggest inefficiencies and potential liquidity issues, which could hinder long-term growth and sustainability.
PaxMedica, Inc. News
PXMD FAQ
What was PaxMedica, Inc.’s price range in the past 12 months?
PaxMedica, Inc. lowest stock price was $0.03 and its highest was $1.19 in the past 12 months.
What is PaxMedica, Inc.’s market cap?
PaxMedica, Inc.’s market cap is $88.39K.
When is PaxMedica, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PaxMedica, Inc.’s earnings last quarter?
Currently, no data Available
Is PaxMedica, Inc. overvalued?
According to Wall Street analysts PaxMedica, Inc.’s price is currently Overvalued.
Does PaxMedica, Inc. pay dividends?
PaxMedica, Inc. does not currently pay dividends.
What is PaxMedica, Inc.’s EPS estimate?
PaxMedica, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PaxMedica, Inc. have?
PaxMedica, Inc. has 126,264,370 shares outstanding.
What happened to PaxMedica, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PaxMedica, Inc.?
Currently, no hedge funds are holding shares in PXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PaxMedica, Inc.
PaxMedica, Inc. is a biopharmaceutical company currently in the clinical development phase, dedicated to advancing anti-purinergic drug therapies (APTs). These innovative treatments are specifically designed to address complex neurological disorders presenting with stubborn and persistent symptoms. The company's primary investigative drug is PAX-101, an intravenous (IV) form of suramin, which is being explored for a variety of conditions. These include autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, post-COVID-19 syndrome (commonly known as "long COVID"), and human African trypanosomiasis. Furthermore, PaxMedica is also developing PAX-102, an intranasal version of suramin, intended for various neurological applications. The company, which was incorporated in 2018 and has its headquarters in Tarrytown, New York, previously operated as Purinix Pharmaceuticals LLC before rebranding to PaxMedica, Inc. in April 2020. It functions as a subsidiary of Tardimed Sciences LLC.
Scinai Immunotherapeutics
―
Aditxt
―
Dermata Therapeutics
―
Psyence Biomedical
―
CDT Equity
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.06% Other Institutional Investors
99.94% Public Companies and
Individual Investors